Autonomix medical, inc. reports third quarter fy2024 financial results and reiterates upcoming key milestones

Company developing potential breakthrough technology for the nervous system initially targeting multi-billion-dollar pancreatic cancer market on track to commence first study ever to evaluate radiofrequency (rf) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer in q1 cy2024 cash runway to fund operations into q1 cy2025 the woodlands, tx, feb. 14, 2024 (globe newswire) -- autonomix medical, inc. (nasdaq: amix) (“autonomix” or the “company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, reported financial results yesterday for the third quarter fy2024 ended december 31, 2023 and provided a corporate update. recent highlights closed $11.2 million in gross proceeds from initial public offering (“ipo”) and commenced trading on nasdaq under the ticker symbol “amix”; completed $8,000,000 all stock-based transaction for exclusive worldwide rights to technology for cardiology field use; completed preclinical safety study to support program advancement into first in human clinical study to treat pancreatic cancer pain through transvascular ablation; completed formation of engineering development team; received ethics committee authorization for proof-of-concept (“poc”) human clinical study evaluating proprietary ablation technology for treatment of pancreatic cancer pain; and launched corporate social media channels: x , linkedin , instagram and facebook.
AMIX Ratings Summary
AMIX Quant Ranking